Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine

Infectious Diseases and Therapy

Volumn 2, Issue 2, 2013, Pages 145-158

  Chin, Ruth ^a,b   Torresi, Joseph ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Booster vaccine; Immunogenicity; Infectious diseases; Japanese encephalitis; Live attenuated vaccine; Vaccines

Indexed keywords

CHIMERIVAX JE; HEPATITIS A VACCINE; JAPANESE ENCEPHALITIS VACCINE; PLACEBO; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

CLINICAL FEATURE; CULEX TRITAENIORHYNCHUS; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS; MOSQUITO; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION LOOP MEDIATED ISOTHERMAL AMPLIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SUSCEPTIBLE POPULATION; SWINE; TRAVEL; VIREMIA; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; WATER BIRD; ZOONOSIS;

EID: 84977159946     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-013-0018-2     Document Type: Review

References (52)

1. Dickerson RB, Newton JR, Hansen JE. Diagnosis and immediate prognosis of Japanese B encephalitis; observations based on more than 200 patients with detailed analysis of 65 serologically confirmed cases. Am J Med. 1952;12(3): 277-88.
2. Kumar R, Mathur A, Singh KB, Sitholey P, Prasad M, Shukla R, et al. Clinical sequelae of Japanese encephalitis in children. Indian J Med Res. 1993;97: 9-13.
3. Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis. 2008;198(4): 493-9.
4. Sohn YM, Tandan JB, Yoksan S, Ji M, Ohrr H. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine. 2008;26(13): 1638-43.
5. Torresi J, McCarthy K, Feroldi E, Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine. 2010;28(50): 7993-8000.
6. Gubler D, Kuno G, Markoff L. In: Knipe D, Howley P, editors. Flaviviruses. 5th ed. Philadelphia: Lippincott William and Wilkins; 2007. p. 1155-252.
7. Pan CH, Chen HW, Huang HW, Tao MH. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J Virol. 2001;75(23): 11457-63.
8. Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in Southeast Asia. J Virol. 2003;77(5): 3091-8.
9. Li MH, Fu SH, Chen WX, Wang HY, Guo YH, Liu QY, et al. Genotype v Japanese encephalitis virus is emerging. PLoS Negl Trop Dis. 2011;5(7): e1231.
10. Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol. 2002;267: 11-48.
11. Wu YC, Huang YS, Chien LJ, Lin TL, Yueh YY, Tseng WL, et al. The epidemiology of Japanese encephalitis on Taiwan during 1966-1997. Am J Trop Med Hyg. 1999;61(1): 78-84.
12. Sohn YM. Japanese encephalitis immunization in South Korea: past, present, and future. Emerg Infect Dis. 2000;6(1): 17-24.
13. Okuno T. An epidemiological review of Japanese encephalitis. World Health Stat Q. 1978;31(2): 120-33.
14. Hills SL, Weber IB, Fischer M. Japanese encephalitis: CDC health information for international travel 'Yellow Book'; 2014. http://wwwnc. cdc. gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/japanese-encephalitis. Accessed Oct 22, 2013.
15. Mani TR, Rao CV, Rajendran R, Devaputra M, Prasanna Y, Hanumaiah et al. Surveillance for Japanese encephalitis in villages near Madurai, Tamil Nadu, India. Trans R Soc Trop Med Hyg. 1991;85(2): 287-91.
16. Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, van den Hurk AF, et al. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust. 1999;170(11): 533-6.
17. Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, Mackenzie JS, et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust. 1996;165(5): 256-60.
18. Ritchie SA, Rochester W. Wind-blown mosquitoes and introduction of Japanese encephalitis into Australia. Emerg Infect Dis. 2001;7(5): 900-3.
19. Li YX, Li MH, Fu SH, Chen WX, Liu QY, Zhang HL, et al. Japanese encephalitis, Tibet, China. Emerg Infect Dis. 2011;17(5): 934-6.
20. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine. 2000;18(Suppl 2): 1-25.
21. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10): 766-74, 74A-74E.
22. Lehtinen VA, Huhtamo E, Siikamaki H, Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol. 2008;43(1): 93-5.
23. Hanson JP, Taylor CT, Richards AR, Smith IL, Boutlis CS. Japanese encephalitis acquired near Port Moresby: implications for residents and travellers to Papua New Guinea. Med J Aust. 2004;181(5): 282-3.
24. Caramello P, Canta F, Balbiano R, Lipani F, Ariaudo S, De Agostini M, et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? J Travel Med. 2007;14(5): 346-8.
25. Ratnam I, Leder K, Black J, Biggs BA, Matchett E, Padiglione A, et al. Low risk of Japanese encephalitis in short-term Australian travelers to Asia. J Travel Med. 2013;20(3): 206-8.
26. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg. 2010;82(5): 930-6.
27. Hatz C, Werlein J, Mutsch M, Hufnagel M, Behrens RH. Japanese encephalitis: defining risk incidence for travelers to endemic countries and vaccine prescribing from the UK and Switzerland. J Travel Med. 2009;16(3): 200-3.
28. Ding D, Hong Z, Zhao SJ, Clemens JD, Zhou B, Wang B, et al. Long-term disability from acute childhood Japanese encephalitis in Shanghai, China. Am J Trop Med Hyg. 2007;77(3): 528-33.
29. Solomon T, Thao LT, Dung NM, Kneen R, Hung NT, Nisalak A, et al. Rapid diagnosis of Japanese encephalitis by using an immunoglobulin M dot enzyme immunoassay. J Clin Microbiol. 1998;36(7): 2030-4.
30. Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis. 1985;151(6): 1093-9.
31. Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT. Use of immunoglobulin m cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol. 2002;9(3): 544-9.
32. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, et al. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg. 1989;40(4): 418-27.
33. Toriniwa H, Komiya T. Rapid detection and quantification of Japanese encephalitis virus by real-time reverse transcription loop-mediated isothermal amplification. Microbiol Immunol. 2006;50(5): 379-87.
34. Parida MM, Santhosh SR, Dash PK, Tripathi NK, Saxena P, Ambuj S, et al. Development and evaluation of reverse transcription-loop-mediated isothermal amplification assay for rapid and real-time detection of Japanese encephalitis virus. J Clin Microbiol. 2006;44(11): 4172-8.
35. Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh. India. Clin Infect Dis. 2009;48(4): 400-6.
36. Hoke CH Jr, Vaughn DW, Nisalak A, Intralawan P, Poolsuppasit S, Jongsawas V, et al. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis. 1992;165(4): 631-7.
37. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet. 2003;361(9360): 821-6.
38. Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, et al. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother. 2012;8(7): 929-37.
39. Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine. 2010;28(3): 834-9.
40. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73(4): 3095-101.
41. Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999;257(2): 363-72.
42. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28(3): 632-49.
43. Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001;75(2): 934-42.
44. Levenbook IS, Pelleu LJ, Elisberg BL. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Stand. 1987;15(4): 305-13.
45. Hardy F. In: Monath TP, editor. Susceptibility and resistance of vector mosquitoes. Boca Raton: CRC Press; 1988.
46. Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002;20(7-8): 1004-18.
47. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003;188(8): 1213-30.
48. Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, Aaskov J, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin. 2010;6(12): 1038-46.
49. Desai K, Coudeville L, Bailleux F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine. 2012;30(15): 2510-5.
50. Halstead SB, Jocobson J. Japanese encephalitis virus vaccines. In: Plotkin S, Orenstien W, Offit P, editors. Vaccines. 5th ed. New York: Saunders Elsevier; 2008. p. 311-52.
51. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J. 2010;29(12): 1111-7.
52. Feroldi E, Capeding MR, Boaz M, Gailhardou S, Meric C, Bouckenooghe A. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother. 2013;9(4): 889-97.